Published in PLoS One on March 12, 2012
Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor α. Clin Vaccine Immunol (2013) 0.97
Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination. PLoS One (2012) 0.93
B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses. J Immunol (2013) 0.91
Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain. Infect Immun (2013) 0.91
Uncovering the components of the Francisella tularensis virulence stealth strategy. Front Cell Infect Microbiol (2014) 0.90
Francisella tularensis SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8. J Immunol (2013) 0.89
Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells. Clin Vaccine Immunol (2014) 0.87
Live attenuated tularemia vaccines: recent developments and future goals. Vaccine (2013) 0.86
Alternative activation of macrophages and induction of arginase are not components of pathogenesis mediated by Francisella species. PLoS One (2013) 0.82
Immunotherapy for tularemia. Virulence (2013) 0.81
Use of a capture-based pathogen transcript enrichment strategy for RNA-Seq analysis of the Francisella tularensis LVS transcriptome during infection of murine macrophages. PLoS One (2013) 0.81
Differential expression of microRNAs in Francisella tularensis-infected human macrophages: miR-155-dependent downregulation of MyD88 inhibits the inflammatory response. PLoS One (2014) 0.80
Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain. Infect Immun (2014) 0.79
Editorial: Leukocytes in tularemia--so many cells, so little time. J Leukoc Biol (2013) 0.79
MyD88-dependent signaling prolongs survival and reduces bacterial burden during pulmonary infection with virulent Francisella tularensis. Am J Pathol (2013) 0.76
A Bioluminescent Francisella tularensis SCHU S4 Strain Enables Noninvasive Tracking of Bacterial Dissemination and the Evaluation of Antibiotics in an Inhalational Mouse Model of Tularemia. Antimicrob Agents Chemother (2016) 0.75
Inclusion of Epitopes That Expand High-Avidity CD4+ T Cells Transforms Subprotective Vaccines to Efficacious Immunogens against Virulent Francisella tularensis. J Immunol (2016) 0.75
Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med (1993) 17.01
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem (2002) 14.34
Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol (1995) 10.65
Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol (1961) 7.52
Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A (1985) 7.15
New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol (2005) 4.53
Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect Immun (2004) 4.31
B lymphocytes: how they develop and function. Blood (2008) 4.07
Growth of Francisella spp. in rodent macrophages. Infect Immun (1991) 3.81
AEROSOL INFECTION OF MAN WITH PASTEURELLA TULARENSIS. Bacteriol Rev (1961) 3.62
Specific immunity to Listeria monocytogenes in the absence of IFN gamma. Immunity (1995) 3.54
Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J Infect Dis (1977) 3.51
Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity (2009) 3.33
Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules. Infect Immun (1992) 3.09
Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J Immunol (2007) 2.78
Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog (2003) 2.61
Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol (1995) 2.57
Factors affecting the escape of Francisella tularensis from the phagolysosome. J Med Microbiol (2004) 2.57
Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112. Infect Immun (2008) 2.53
Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect Immun (1996) 2.50
Francisella tularensis inhibits Toll-like receptor-mediated activation of intracellular signalling and secretion of TNF-alpha and IL-1 from murine macrophages. Cell Microbiol (2003) 2.46
Modulation of biogenesis of the Francisella tularensis subsp. novicida-containing phagosome in quiescent human macrophages and its maturation into a phagolysosome upon activation by IFN-gamma. Cell Microbiol (2005) 2.46
Tularaemia. Eur Respir J (2003) 2.46
Studies with MHC-deficient knock-out mice reveal impact of both MHC I- and MHC II-dependent T cell responses on Listeria monocytogenes infection. J Immunol (1994) 2.39
Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity. J Immunol (2006) 2.16
Experimental murine tularemia caused by Francisella tularensis, live vaccine strain: a model of acquired cellular resistance. Microb Pathog (1987) 2.13
Francisella tularensis live vaccine strain induces macrophage alternative activation as a survival mechanism. J Immunol (2008) 2.06
Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis (1994) 2.04
In vivo clearance of an intracellular bacterium, Francisella tularensis LVS, is dependent on the p40 subunit of interleukin-12 (IL-12) but not on IL-12 p70. Infect Immun (2002) 2.02
Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis. J Leukoc Biol (1991) 2.01
Studies on human infection with Pasteurella tularensis; comparison of streptomycin and chloramphenicol in the prophylaxis of clinical disease. Trans Assoc Am Physicians (1957) 2.01
Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect Immun (2005) 1.97
Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity. Infect Immun (2001) 1.91
Infection caused by Francisella philomiragia (formerly Yersinia philomiragia). A newly recognized human pathogen. Ann Intern Med (1989) 1.89
Matrix metalloproteinase 9 activity enhances host susceptibility to pulmonary infection with type A and B strains of Francisella tularensis. J Immunol (2007) 1.85
Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog (2008) 1.81
Infraspecific taxonomy of tularemia agent Francisella tularensis McCoy et Chapin. J Hyg Epidemiol Microbiol Immunol (1982) 1.80
Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS. Microb Pathog (2002) 1.80
Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect Immun (1994) 1.75
Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J Immunol (1996) 1.73
Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infect Immun (1999) 1.70
Microarray analysis of human monocytes infected with Francisella tularensis identifies new targets of host response subversion. PLoS One (2008) 1.67
Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells. Infect Immun (2008) 1.66
Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann N Y Acad Sci (1992) 1.66
Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways. J Immunol (2008) 1.64
Resistance of Francisella tularensis strains against reactive nitrogen and oxygen species with special reference to the role of KatG. Infect Immun (2007) 1.64
Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol (2007) 1.61
Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4. Infect Immun (2008) 1.56
Role of CD1d-restricted NKT cells in microbial immunity. Infect Immun (2003) 1.55
The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology (2011) 1.53
Type I IFN signaling constrains IL-17A/F secretion by gammadelta T cells during bacterial infections. J Immunol (2010) 1.52
CD4+ and CD8+ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice. Infect Immun (1994) 1.50
Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of Francisella tularensis. Microb Pathog (2004) 1.50
Role of T cell subsets in immunity against intracellular bacteria: experimental infections of knock-out mice with Listeria monocytogenes and Mycobacterium bovis BCG. Immunobiology (1994) 1.49
Early activation of NK cells after lung infection with the intracellular bacterium, Francisella tularensis LVS. Cell Immunol (2005) 1.47
Macrophage pro-inflammatory response to Francisella novicida infection is regulated by SHIP. PLoS Pathog (2006) 1.38
An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine (2008) 1.35
Lung CD4-CD8- double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain. J Immunol (2010) 1.34
Cutting edge: mutation of Francisella tularensis mviN leads to increased macrophage absent in melanoma 2 inflammasome activation and a loss of virulence. J Immunol (2010) 1.33
Transcriptional profiling of host responses in mouse lungs following aerosol infection with type A Francisella tularensis. J Med Microbiol (2006) 1.29
Deletion of ripA alleviates suppression of the inflammasome and MAPK by Francisella tularensis. J Immunol (2010) 1.27
Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection. Eur J Immunol (2008) 1.26
Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4. Proc Natl Acad Sci U S A (2008) 1.21
Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy. Clin Vaccine Immunol (2009) 1.20
Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. Vaccine (2008) 1.19
The role of IL-12, IL-23 and IFN-gamma in immunity to viruses. Cytokine Growth Factor Rev (2004) 1.18
Toll-like receptor 4 (TLR4) does not confer a resistance advantage on mice against low-dose aerosol infection with virulent type A Francisella tularensis. Microb Pathog (2004) 1.15
Features of sepsis caused by pulmonary infection with Francisella tularensis Type A strain. Microb Pathog (2011) 1.11
Relapse of tularemia after aminoglycoside therapy: case report and discussion of therapeutic options. Clin Infect Dis (1995) 1.10
IFN-β mediates suppression of IL-12p40 in human dendritic cells following infection with virulent Francisella tularensis. J Immunol (2011) 1.05
A novel role for plasmin-mediated degradation of opsonizing antibody in the evasion of host immunity by virulent, but not attenuated, Francisella tularensis. J Immunol (2009) 1.03
The presence of CD14 overcomes evasion of innate immune responses by virulent Francisella tularensis in human dendritic cells in vitro and pulmonary cells in vivo. Infect Immun (2009) 1.03
The role of T cell subsets and cytokines in the regulation of intracellular bacterial infection. Braz J Med Biol Res (1998) 1.01
Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains. Infect Immun (2011) 1.00
IFN-gamma therapy of tuberculosis and related infections. J Interferon Cytokine Res (2007) 1.00
Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens. PLoS Pathog (2010) 0.97
Natural killer T cells are critical for dendritic cells to induce immunity in Chlamydial pneumonia. Am J Respir Crit Care Med (2008) 0.96
Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs. Vaccine (2010) 0.94
Treatment of tularemia with levofloxacin. Clin Microbiol Infect (2001) 0.92
A comparative study of the treatment of tularemia with immune serum, hyperimmune serum and streptomycin. Am J Med (1946) 0.90
A novel p40-independent function of IL-12p35 is required for progression and maintenance of herpes stromal keratitis. Invest Ophthalmol Vis Sci (2010) 0.86
Inhibition of airway eosinophilia and pulmonary pathology in a mouse model of allergic asthma by the live vaccine strain of Francisella tularensis. Clin Exp Allergy (2008) 0.79
Lymphotoxin-alpha plays only a minor role in host resistance to respiratory infection with virulent type A Francisella tularensis in mice. Mediators Inflamm (2008) 0.78
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67
A Tn7-based broad-range bacterial cloning and expression system. Nat Methods (2005) 4.66
Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med (2002) 3.88
Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect (2003) 2.48
Innate and adaptive immunity to Francisella. Ann N Y Acad Sci (2007) 2.32
Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A (2003) 2.18
Lung environment determines unique phenotype of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol (2009) 2.10
Intracellular biology and virulence determinants of Francisella tularensis revealed by transcriptional profiling inside macrophages. Cell Microbiol (2009) 2.00
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med (2013) 1.98
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81
Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4. Infect Immun (2008) 1.56
Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med (2004) 1.44
Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain. Emerg Infect Dis (2015) 1.31
Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J Immunol (2007) 1.29
Virulence variation among isolates of western equine encephalitis virus in an outbred mouse model. J Gen Virol (2009) 1.11
Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection. Infect Immun (2012) 1.05
IFN-β mediates suppression of IL-12p40 in human dendritic cells following infection with virulent Francisella tularensis. J Immunol (2011) 1.05
Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers. Viruses (2012) 1.04
A novel role for plasmin-mediated degradation of opsonizing antibody in the evasion of host immunity by virulent, but not attenuated, Francisella tularensis. J Immunol (2009) 1.03
The presence of CD14 overcomes evasion of innate immune responses by virulent Francisella tularensis in human dendritic cells in vitro and pulmonary cells in vivo. Infect Immun (2009) 1.03
Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor α. Clin Vaccine Immunol (2013) 0.97
Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens. PLoS Pathog (2010) 0.97
Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, F. tularensis LVS. PLoS Pathog (2012) 0.96
Infection of mice with Francisella as an immunological model. Curr Protoc Immunol (2011) 0.96
Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother (2013) 0.95
Molecular mechanisms of filovirus cellular trafficking. Microbes Infect (2003) 0.95
A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques. J Infect Dis (2013) 0.94
Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs. Vaccine (2010) 0.94
Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination. PLoS One (2012) 0.93
A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Infect Immun (2008) 0.92
NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cell Microbiol (2007) 0.92
B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses. J Immunol (2013) 0.91
Hamster-adapted Sin Nombre virus causes disseminated infection and efficiently replicates in pulmonary endothelial cells without signs of disease. J Virol (2013) 0.90
Essential genes from Arctic bacteria used to construct stable, temperature-sensitive bacterial vaccines. Proc Natl Acad Sci U S A (2010) 0.89
Francisella tularensis SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8. J Immunol (2013) 0.89
T-bet regulates immunity to Francisella tularensis live vaccine strain infection, particularly in lungs. Infect Immun (2014) 0.83
Alternative activation of macrophages and induction of arginase are not components of pathogenesis mediated by Francisella species. PLoS One (2013) 0.82
Virulent and avirulent strains of equine arteritis virus induce different quantities of TNF-alpha and other proinflammatory cytokines in alveolar and blood-derived equine macrophages. Virology (2003) 0.80
Francisella tularensis LVS surface and membrane proteins as targets of effective post-exposure immunization for tularemia. J Proteome Res (2014) 0.79
Human body temperature and new approaches to constructing temperature-sensitive bacterial vaccines. Cell Mol Life Sci (2011) 0.78
Toxoplasmosis in a Hawaiian monk seal (Monachus schauinslandi). J Parasitol (2005) 0.78
Primary site of sea lion carcinomas. Vet Pathol (2010) 0.76
Virulent Francisella tularensis destabilize host mRNA to rapidly suppress inflammation. J Innate Immun (2014) 0.75